Tumor suppressive microRNA‑429 regulates cellular function by targeting VEGF in clear cell renal cell carcinoma

Chen,Duqun; Li,Yuchi; Li,Yifan; Jin,Lu; Su,Zhengming; Yu,Zuhu; Yang,Shangqi; Mao,Xiangming; Lai,Yongqing

doi:10.3892/mmr.2015.4653

Tumor suppressive microRNA‑429 regulates cellular function by targeting VEGF in clear cell renal cell carcinoma

Authors:
- Duqun Chen
- Yuchi Li
- Yifan Li
- Lu Jin
- Zhengming Su
- Zuhu Yu
- Shangqi Yang
- Xiangming Mao
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China, The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: December 7, 2015 https://doi.org/10.3892/mmr.2015.4653
Pages: 1361-1366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clear cell renal cell carcinoma (ccRCC) is the predominant and most aggressive type of kidney malignancy, however, the mechanism underlying its carcinogenesis remains to be elucidated. The present study aimed to determine the expression and function of microRNA (miR)‑429 in ccRCC carcinogenesis. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression of miR‑429 in ccRCC specimens. Following transfection of miR‑429 synthetic mimics, the expression of miR‑429 was examined and cell proliferation, cell migration, apoptosis and luciferase assays were conducted in ccRCC cell lines. The results demonstrated that expression of miR‑429 was decreased in ccRCC cells. In addition, upregulation of miR‑429 by transfection of mimics reduced cellular proliferation and migration, and induced apoptosis in ACHN and 786‑0 cell lines. Furthermore, miR‑429 decreased the 3'UTR luciferase activity of vascular endothelial growth factor (VEGF) and c‑MYC, and RT‑qPCR analysis demonstrated that the cancer cells transfected with miR‑429 mimics exhibited decreased expression of VEGF, but not c‑MYC. To the best of our knowledge, the present study was the first to reveal that downregulated miR‑429 functioned as a tumor suppressor by restraining cellular proliferation and migration, and inducing apoptosis, as well as targeting VEGF in ccRCC cells.

View Figures

View References

1	Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
2	Cho E, Adami HO and Lindblad P: Epidemiology of renal cell cancer. Hematol Oncol Clin North Am. 25:651–665. 2011. View Article : Google Scholar : PubMed/NCBI
3	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
4	Keefe SM, Nathanson KL and Rathmell WK: The molecular biology of renal cell carcinoma. Semin Oncol. 40:421–428. 2013. View Article : Google Scholar : PubMed/NCBI
5	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010.
6	Koscianska E, Baev V, Skreka K, Oikonomaki K, Rusinov V, Tabler M and Kalantidis K: Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol. 8:792007. View Article : Google Scholar : PubMed/NCBI
7	Schmidt U and Begley CG: Cancer diagnosis and microarrays. Int J Biochem Cell Biol. 35:119–124. 2003. View Article : Google Scholar
8	Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
9	Walter BA, Valera VA, Pinto PA and Merino MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer. 4:350–357. 2013. View Article : Google Scholar : PubMed/NCBI
10	Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ and van Poppel H: Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One. 7:e382982012. View Article : Google Scholar : PubMed/NCBI
11	Aqeilan RI, Calin GA and Croce CM: miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar
12	Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar
14	Sun Y, Shen S, Tang H, Xiang J, Peng Y, Tang A, Li N, Zhou W, Wang Z, Zhang D, Xiang B, et al: miR-429 identified by dynamic transcriptome analysis is a new candidate biomarker for colorectal cancer prognosis. OMICS. 18:54–64. 2014. View Article : Google Scholar :
15	Sun T, Wang C, Xing J and Wu D: miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur J Cancer. 47:2552–2559. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Li M, Zang W, Ma Y, Wang N, Li P, Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar
17	Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
18	Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW and Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
19	Levine RJ: An IRB-approved protocol on the use of human fetal tissue. IRB. 11:7–8. 1989. View Article : Google Scholar : PubMed/NCBI
20	Yoon S and De Micheli G: Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics. 21(Suppl 2): ii93–ii100. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, Minna JD and Wu X: Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73:4801–4809. 2013. View Article : Google Scholar : PubMed/NCBI
22	Wu D, Pan H, Zhou Y, Zhou J, Fan Y and Qu P: microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep. 9:2491–2498. 2014.PubMed/NCBI
23	Mangolini A, Bonon A, Volinia S, Lanza G, Gambari R, Pinton P, Russo GR, Del Senno L, Dell'Atti L and Aguiari G: Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio. 4:952–965. 2014. View Article : Google Scholar : PubMed/NCBI
24	Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, Riedmiller H and Kneitz B: Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer. 14:252014. View Article : Google Scholar : PubMed/NCBI
25	Zhang T, Niu X, Liao L, Cho EA and Yang H: The contributions of HIF-target genes to tumor growth in RCC. PLoS One. 8:e805442013. View Article : Google Scholar : PubMed/NCBI
26	Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, et al: The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 19:5218–5226. 2013. View Article : Google Scholar : PubMed/NCBI
27	Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S and Muzzonigro G: Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int. 2013:4191762013. View Article : Google Scholar : PubMed/NCBI
28	Gupta S and Spiess PE: The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol. 5:223–232. 2013. View Article : Google Scholar : PubMed/NCBI
29	Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC, Lai MK and Lin JY: MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett. 273:35–43. 2009. View Article : Google Scholar